

51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Izotropic Corporation (the “**Company**”)
800-15355 24th Avenue
Suite 424
Surrey, BC V4A 2H9

Item 2 Date of Material Change

September 19, 2025

Item 3 News Release

The news release dated September 19, 2025 disseminated via NewsFile.

Item 4 Summary of Material Change

On September 19, 2025, the Company announced a closing of a non-brokered private placement for gross proceeds of \$375,000 (the “**Offering**”). The Offering consisted, in total, of the issuance of 1,500,000 units (the “**Units**”) at a price of \$0.25 per Unit. Each Unit was comprised of one common share in the capital of the Company and one common share purchase warrant (each a “**Warrant**”) with each Warrant entitling its holder to purchase one common share in the capital of the Company for a price of \$0.50 for a period of thirty-six (36) months from the issuance date. In connection with the Offering, the Company paid compensation to certain eligible finders consisting of cash finder’s fees in an aggregate amount of \$3,500.00 and the issuance of 14,000 broker warrants (each a “**Broker Warrant**”). Each Broker Warrant is exercisable for a period of thirty-six (36) months from the issuance date at an exercise price of \$0.25.

Item 5 Full Description of Material Change

The material change is fully described in Item 4 above and in the attached news release which has been filed on SEDAR.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Executive Officer

Robert Thast, Chief Executive Officer
Telephone: 1 (833) 496-2677

Item 9 Date of Report

September 19, 2025

September 19, 2025

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR
DISSEMINATION IN THE UNITED STATES

Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants

VANCOUVER, British Columbia, and SACRAMENTO, Calif., September. 19, 2025, **Izotropic Corporation** (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**) ("**Izotropic**", or the "**Company**"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its [August 26th announcement](#) it has completed a non-brokered private placement financing (the "**Offering**"), whereby the Company issued 1,500,000 units (each, a "**Unit**") at a price of \$0.25 per Unit for gross proceeds of \$375,000.

Each Unit consists of one common share and one transferable warrant (each, a "**Warrant**"), and each Warrant entitles the holder to purchase one additional share at a price of \$0.50 per share for a period of three (3) years from closing of the Offering.

The use of proceeds from the Offering will be used for general working capital.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

An insider of the Company acquired 100,000 Units in the Offering which constituted a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The issuance to the insider is exempt from the valuation requirement of MI 61-101 by the virtue of the exemption contained in section 5.5(b) as the Company's shares are

not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(1)(a) as the value of the Units did not exceed 25% of the Company's market capitalization.

The Company paid an aggregate of \$3,500 and issued an aggregate of 14,000 broker warrants in connection with the closing of the Offering. Each broker warrant will entitle the holder to purchase one additional share at a price of \$0.25 per share for a period of three (3) years from closing of the Offering.

Completion of this Offering is subject to a number of conditions, including, without limitation, receipt of all necessary regulatory approvals.

None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "**1933 Act**"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

The Company also announces that it has entered into the following two service agreements:

1. A digital marketing services agreement with 1822053 Alberta Ltd., operating as Evolux Capital ("**Evolux**"), an arm's-length party. Evolux has been engaged to provide investor awareness and digital marketing services, including the creation and distribution of social media advertising, the development and implementation of communications strategies, assistance with brand development, and coordination with advertising and social media partners. The engagement is for an initial twelve-month term ending September 15, 2026, with total consideration of CAD \$60,000 (plus applicable taxes), payable in advance. The Company confirms that Evolux holds 94,000 common shares, 80,000 share purchase warrants, and 200,000 previously granted stock options of the Company. The common shares and warrants were acquired through a combination of private placements and market purchases. No additional securities are being issued in connection with this agreement. Evolux Capital can be contacted at evoluxcapital@gmail.com or 126 Mitchell Crescent, Blackfalds, Alberta, T4M 0H6.

2. A service agreement for the provision of investor relations services. The Company has entered into a Service Agreement dated effective September 19, 2025, with Departures Capital Inc. (“DC”), under which DC will provide strategic consulting, investor communications, digital media production, and other related services to Izotropic for a one-year term expiring September 19, 2026. Under the agreement, Izotropic will pay CAD \$25,000 (plus applicable taxes), payable in advance of the provision of any services. DC is arm’s length to Izotropic and, to the knowledge of Izotropic, neither DC nor their principals have any present equity interest in the Company’s securities, directly or indirectly, or any right to acquire any equity interest. DC can be contacted at contact@departurescapital.com or #1500 – 409 Granville Street, Vancouver, British Columbia V6C 1T2.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer

Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1

Email: bthast@izocorp.com

James Gagnon, International Communications

Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2

Email: jgagnon@izocorp.com

General and Corporate Inquiries

Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3

Email: info@izocorp.com